sorafenib
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
MARCH 16, 2022
FDA Approves New Indication for Lenvima for HCC
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 17, 2018
FDA Grants Opdivo New Indication for HCC Patients Previously Treated With Sorafenib
The U.S. burden of hepatocellular carcinoma is significant. A recent ACS report noted that death rates from liver ...
OCTOBER 2, 2017
Load more